Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Videos

Here are the top 5 biosimilar articles for the week of September 18, 2023.

The Top 5 Biosimilar Articles for the Week of September 18

Articles

The European Commission approved the first aflibercept biosimilar, which will be used to treat patients with age-related macular degeneration and diabetic macular edema.

European Commission Approves First Aflibercept Biosimilar

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.

In the final part of a 3-part series, Sarfaraz K. Niazi, PhD, gives his take on the FDA's recent workshop dedicated to streamlining biosimilar development and his opinion on what the industry can learn from the webinar presenters.

Part 3: BioRationality—FDA Webinar on Biosimilars Efficacy Testing Marks Major Step Forward

A study evaluating the real-world impact of treating patients with inflammatory bowel disease (IBD) with an adalimumab biosimilar found that providing patient questionnaires early can be useful for identifying those at a higher risk of treatment discontinuation.

Patient Surveys Provide Insight Into Real-World Adalimumab Biosimilar Use in IBD

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Understanding and Improving Access of Biosimilars in Oncology

Biosimilars in Oncology: Addressing Awareness

Current State of Biosimilars: Approval, Availability, and Efficacy

Biosimilars in Oncology: Equivalency and Cost

Are Biosimilar Costs a Factor for Patients?

Biosimilars: Addressing Roadblocks to Market Adoption

Switching to Available Biosimilars in Oncology

Determining Biosimilars' Role in the Formulary

Market-Access Considerations for Biosimilars in Oncology

Where Do Biosimilars Fit in to the Treatment Landscape?

Multiple Biosimilars for a Single-Reference Biologic  

Strategies for Incorporating Biosimilars Into Care Plans

Incorporating Biosimilars in Oncology: Working Collaboratively

Economic Impact of Biosimilars in Oncology

Biosimilars in Oncology: Long-Term Financial Benefit

Competition in the Biosimilar Marketplace

Biosimilars in Oncology: Future Directions